Dendritic cell vaccines.
Dendritic cells are antigen-presenting cells that have been shown to stimulate tumor antigen-specific T cell responses in preclinical studies. Consequently, there has been intense interest in developing dendritic cell based cancer vaccines. A variety of methods for generating dendritic cells, loading them with tumor antigens, and administering them to patients have been described. In recent years, a number of early phase clinical trials have been performed and have demonstrated the safety and feasibility of dendritic cell immunotherapies. A number of these trials have generated valuable preliminary data regarding the clinical and immunologic response to DC-based immunotherapy. The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
ISSN
Publication Date
Volume
Start / End Page
Location
Related Subject Headings
- Humans
- Dendritic Cells
- Clinical Trials as Topic
- Cancer Vaccines
- Biochemistry & Molecular Biology
- 1116 Medical Physiology
- 1112 Oncology and Carcinogenesis
- 0601 Biochemistry and Cell Biology
Citation
Published In
DOI
ISSN
Publication Date
Volume
Start / End Page
Location
Related Subject Headings
- Humans
- Dendritic Cells
- Clinical Trials as Topic
- Cancer Vaccines
- Biochemistry & Molecular Biology
- 1116 Medical Physiology
- 1112 Oncology and Carcinogenesis
- 0601 Biochemistry and Cell Biology